Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial The Lancet 6 February 2021;397(10273):475-486
Date
02/06/2021
DOI
10.1016/S0140-6736(21)00126-4Scopus ID
2-s2.0-85100381587 (requires institutional sign-in at Scopus site)
118 CitationsAuthor List
Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A
Author
Kenneth Brian Gordon MD Chair, Professor in the Dermatology department at Medical College of Wisconsin